177 related articles for article (PubMed ID: 7881588)
21. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
22. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.
Ehrenforth S; Kreuz W; Scharrer I; Linde R; Funk M; Güngör T; Krackhardt B; Kornhuber B
Lancet; 1992 Mar; 339(8793):594-8. PubMed ID: 1347102
[TBL] [Abstract][Full Text] [Related]
23. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
[No Abstract] [Full Text] [Related]
24. Inhibitors: resolving diagnostic and therapeutic dilemmas.
Dimichele D
Haemophilia; 2002 May; 8(3):280-7. PubMed ID: 12010424
[TBL] [Abstract][Full Text] [Related]
25. How I manage patients with inherited haemophilia A and B and factor inhibitors.
Ljung RCR
Br J Haematol; 2018 Feb; 180(4):501-510. PubMed ID: 29270992
[TBL] [Abstract][Full Text] [Related]
26. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
Astermark J
Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of hemophiliacs with inhibitors].
Fujimaki M
Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
[No Abstract] [Full Text] [Related]
28. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
[TBL] [Abstract][Full Text] [Related]
29. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
[TBL] [Abstract][Full Text] [Related]
30. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
Nilsson IM; Hedner U
Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
[TBL] [Abstract][Full Text] [Related]
32. Transfusion support for haemophiliacs.
Allain JP
Clin Haematol; 1984 Feb; 13(1):99-117. PubMed ID: 6426835
[No Abstract] [Full Text] [Related]
33. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P
Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742
[TBL] [Abstract][Full Text] [Related]
34. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy for haemophilia: prospects and challenges to prevent or reverse inhibitor formation.
Scott DW; Lozier JN
Br J Haematol; 2012 Feb; 156(3):295-302. PubMed ID: 22055221
[TBL] [Abstract][Full Text] [Related]
36. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
DiMichele DM; Kroner BL;
Thromb Haemost; 2002 Jan; 87(1):52-7. PubMed ID: 11848456
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group.
Sultan Y
Thromb Haemost; 1992 Jun; 67(6):600-2. PubMed ID: 1509398
[TBL] [Abstract][Full Text] [Related]
38. Retrospective study of inhibitor formation in Japanese hemophiliacs.
Kamiya T; Takahashi I; Saito H
Int J Hematol; 1995 Oct; 62(3):175-81. PubMed ID: 8589362
[TBL] [Abstract][Full Text] [Related]
39. Current concepts in diagnosis and management of hemophilia.
Aledort LM
Hosp Pract (Off Ed); 1982 Oct; 17(10):77-84, 89-92. PubMed ID: 6811410
[No Abstract] [Full Text] [Related]
40. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry.
Haya S; López MF; Aznar JA; Batlle J;
Haemophilia; 2001 Mar; 7(2):154-9. PubMed ID: 11260274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
